NCT00612456 - To Evaluate the Pharmacodynamics, Safety, and Pharmacokinetics of Pazopanib Drops in Adult Subjects With Neovascular AMD | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 5, 2008

Primary Completion Date

January 1, 2009

Study Completion Date

June 17, 2009

Conditions

Macular Degeneration

Interventions

DRUG

Pazopanib

Pazopanib eye drops formulation

Trial Locations (27)

2145

GSK Investigational Site, Sydney

2150

GSK Investigational Site, Sydney

3000

GSK Investigational Site, Leuven

6009

GSK Investigational Site, Perth

10122

GSK Investigational Site, Turin

15213

GSK Investigational Site, Pittsburgh

20132

GSK Investigational Site, Milan

20157

GSK Investigational Site, Milan

27157

GSK Investigational Site, Winston-Salem

33334

GSK Investigational Site, Fort Lauderdale

33880

GSK Investigational Site, Winter Haven

34129

GSK Investigational Site, Trieste

35128

GSK Investigational Site, Padua

46280

GSK Investigational Site, Indianapolis

48105

GSK Investigational Site, Ann Arbor

49525

GSK Investigational Site, Grand Rapids

50134

GSK Investigational Site, Florence

77030

GSK Investigational Site, Houston

78705

GSK Investigational Site, Austin

84132

GSK Investigational Site, Salt Lake City

85704

GSK Investigational Site, Tucson

90211

GSK Investigational Site, Beverly Hills

91105

GSK Investigational Site, Pasadena

95841

GSK Investigational Site, Sacramento

02111

GSK Investigational Site, Boston

08755

GSK Investigational Site, Toms River

Unknown

GSK Investigational Site, Melbourne